Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

We conducted this study to determine the feasibility and safety of cladribine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv). Cladribine 5.6 mg/m(2) given IV over 2 hours daily for 5 days was followed ∼ 1 month later with rituximab 375 mg/m(2) IV weekly...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ravandi, Farhad, O'Brien, Susan, Jorgensen, Jeffrey, Pierce, Sherry, Faderl, Stefan, Ferrajoli, Alessandra, Koller, Charles, Challagundla, Pramoda, York, Sergernne, Brandt, Mark, Luthra, Rajyalakshmi, Burger, Jan, Thomas, Deborah, Keating, Michael, Kantarjian, Hagop
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2011
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081440/
https://ncbi.nlm.nih.gov/pubmed/21821712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-351502
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares